HBW Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Geisha-Inspired Tatcha Is Unilever's Latest US Prestige Skin-Care Addition

Executive Summary

Unilever acquires ‘modern, prestige’ skin care firm Tatcha in a reported $500m deal. Tatcha's comprises dozens of items formulated with green tea, rice and algae. Unilever continues seeking beauty and personal care deals, which accounted for 70% of its acquired turnover in recent years.

You may also be interested in...



Unilever Gets Portfolio In Order While Riding Prestige Beauty, Functional Nutrition Growth

Unilever’s prestige beauty business, bulked up by acquisitions over the past five years, achieved 21% underlying sales growth in the FY 2021 first quarter. The firm has formed a new business unit, Elida Beauty, to house a number of smaller, non-core beauty and personal-care brands accounting for around 600m in revenues following talk of possible divestitures.

Unilever Values Beauty, Supplement Sectors As It Considers Leaving Others

Unilever reported 0.5% full-year sales growth for the beauty and personal care division to 5.6bn and overall growth was 2.9% to 52bn, but the fourth quarter was its weakest in more than a decade, with reported sales growth at 1.5% to 12.6bn.

Unilever Q1: Aggressive M&A Paying Off; Oral Care Cited As Space To ‘Watch’

Anglo-Dutch firm’s prestige business, created in recent years through acquisitions such as Hourglass, Dermalogica and Kate Sommerville, grew by double digits in the first quarter. Oral care declined, but CEO Alan Jope is optimistic about the segment’s future.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

RS148906

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel